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Abstract: Tumor progression may be driven by a small subpopulation of cancer stem 
cells (CSCs characterized by CD44+/CD24− phenotype). We investigated the influence of a 
newly developed thienopyridine anticancer compound (3-amino-5-oxo-N-naphthyl-5,6,7, 
8-tetrahydrothieno[2,3-b]quinoline-2-carboxamide, 1) on the growth, survival and glycophe-
notype (CD15s and GM3 containing neuraminic acid substituted with acetyl residue, NeuAc) 
of breast and prostate cancer stem/progenitor-like cell population. MDA-MB-231 and Du-145 
cells were incubated with compound 1 alone or in combination with paclitaxel. The cellular 
metabolic activity was determined by the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide (MTT) assay. The type of cell death induced by 48-h treatment was assessed using 
a combination of Annexin-V-FITC and propidium iodide staining. Flow cytometric analysis 
was performed to detect the percentage of CD44+/CD24− cells, and GM3 and CD15s positive 
CSCs, as well as the expression of GM3 and CD15s per one CSC, in both cell lines. Compound 
1 produces a dose- and time-dependent cytotoxicity, mediated mainly by apoptosis in breast 
cancer cells, and slightly (2.3%) but statistically significant lowering breast CSC subpopulation. 
GM3 expression per one breast CSC was increased, and the percentage of prostate GM3+ CSC 
subpopulation was decreased in cells treated with compound 1 compared with non-treated cells. 
The percentage of CD15s+ CSCs was lower in both cell lines after treatment with compound 1. 
Considering that triple-negative breast cancers are characterized by an increased percentage of 
breast CSCs and knowing their association with an increased risk of metastasis and mortality, 
compound 1 is a potentially effective drug for triple-negative breast cancer treatment.
Keywords: breast, prostate, cancer stem cells, CD44+/CD24−, GM3, CD15s
Introduction
Metastasis, tumor recurrence and resistance to therapy are the leading causes of 
death for patients with prostate and breast cancer. Tumor progression may be driven 
by cancer stem cells (CSCs) that have the ability to self-renew and to regenerate the 
primary tumor phenotypic heterogeneity.1,2 The CD44+/CD24− phenotype defines the 
subpopulation of cancer cells with stem-like qualities.3 It is believed that CD44+/CD24− 
CSCs are involved in therapy resistance in various cancers, including triple-negative 
breast cancer (breast cancer that does not express the genes for estrogen receptor, 
progesterone receptor and the human epidermal growth factor receptor-2) and prostate 
cancer.1,2 Treatment of triple-negative breast cancers with cytotoxic chemotherapeutic 
such as paclitaxel shows only 21% of pathologic complete response rate in the breast 
and axilla.4 Prostate cancer exhibits high intrinsic drug resistance with sensitivity to 
few chemotherapeutics once androgen deprivation fails.5
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MDA-MB-231 (a triple-negative breast cancer)6 and 
Du-145 (androgen-independent prostate cancer)7 cell lines 
contain large amount of GM3 ganglioside. GM3 is the 
simplest acidic glycosphingolipid, containing N-acetyl 
neuraminic (NeuAc) or N-glycolylneuraminic acid (NeuGc). 
GM3 (NeuGc) ganglioside is especially interesting in breast 
cancer immunotherapy with highly specific anti-GM3 
(NeuGc) ganglioside monoclonal antibody due to its restric-
tive expression in normal human tissues.8 GM3 (NeuAc) is 
known as a marker of the membrane microdomains called 
lipid rafts. Lipid rafts are functional units in cell mem-
branes, biochemically characterized as detergent insoluble,9 
involved in many immune signal transduction processes,10 
including CD44 and endothelial selectin-mediated neutrophil 
signaling.11,12 Glycoprotein CD44 and CD15s (sialyl-Lewis x) 
on cancer cells enable malignant infiltration in different 
tissues.13 A novel mechanism of regulating breast cancer cell 
migration involves palmitoylation-dependent alterations in 
the lipid raft affiliation of CD44.14 Minor changes in lipid 
raft GM3 (NeuAc) content can cause dramatic changes in 
protein structure and activity. In the case of insulin resistance, 
enhanced GM3 lipid raft content disturbs insulin receptor 
function.15 In our study, the change in number of GM3 mol-
ecules per one cell after the drug treatment, expressed as GM3 
geometric mean fluorescence intensity (GMI), would indicate 
the possible involvement of disturbed GM3 lipid raft content 
in the cytotoxic effects of thieno[2,3-b]pyridine inhibitors.
Knowing that targeting of the CSC population is a 
promising approach to overcome tumor relapse and resistance, 
the aim of this study was to determine the percentage of CSCs 
after treatment with newly synthesized thieno[2,3-b]pyridine 
anticancer agent.16 It is now established that this class of 
thieno[2,3-b]pyridines has potent anticancer activity against 
a variety of tumor cell lines.17–19 The molecular structure of 
compound 1 used in this study is shown in Figure 1. The effi-
cacy of the thieno[2,3-b]pyridines was discovered by virtual 
high-throughput screen (vHTS) against the phospholipase 
C-γ2 (PLC-γ2) isoform.20 The administration of thieno[2,3-b]
pyridines causes the breast cancer cell line MDA-MB-231 
to be severely growth restricted, rounded and blebbing of 
the plasma membrane, G
2
/M phase population increase in 
the cell cycle and decrease in motility as reflected in slowed 
proliferation in scratch assays.21 These effects on MDA-
MB-231 are more in line with the inhibition of the PLC-δ1 
and δ2 isoforms making them the most plausible target for 
this class of compounds.21 However, it is quite possible 
that other biomolecular targets are affected, contributing 
to the overall efficacy of the thieno[2,3-b]pyridines, for 
example, tyrosyl-DNA phosphodiesterase I.22
In this study, cell metabolism after administration of 
derivative 1 alone and in combination with paclitaxel was 
assessed by MTT assays. Flow cytometry was used to deter-
mine CD44, CD24, CD15s and GM3 (NeuAc) expression, 
as well as early and late apoptosis and necrosis (Annexin-
V-FITC and propidium iodide staining).
Materials and methods
chemistry
3-Amino-5-oxo-N-naphthyl-5,6,7,8-tetrahydrothieno[2,3-b]
quinoline-2-carboxamide (1) (Figure 1) was dissolved in 
DMSO. Compound 1 has a reported growth inhibition 
at 50% (GI
50
) at 298 nM for MDA-MB-231 and 327 nM 
for Du-145, and a total growth inhibition (TGI) of 4.1 μM 
for MDA-MB-231 and 6.7 μM for Du-145 using the 
sulforhodamine B assay.19 Furthermore, the concentration of 
an inhibitor (IC
50
) value for MDA-MB-231 is reported to be 
690 nM using the thymidine uptake assay.21
cell lines
Cancer cell lines were grown in a humidified incubator at 
37°C and 5% CO
2
 in DMEM (for MDA-MB-231 cells; 
Sigma-Aldrich, Steinheim, Germany) and in RPMI-1640 
media (for Du-145 cells; EuroClone, Milan, Italy) contain-
ing 10% fetal bovine serum (EuroClone) and 1% antibiotics 
(EuroClone). According to the provisions of Article 16 of the 
School of Medicine in Split Code of Ethics, the Committee 
decided that the research in question is in accordance with the 
provisions of the Code of Ethics which regulate research on 
human subjects in scientific, research and professional work 
and with the ethical principles of Declaration of Helsinki.
cytotoxic activity assay
Cell viability was determined by measured cell metabo-
lism using a MTT assay.23 An equal numbers of cells 
(104 cells/100 μL) were plated in three replicates and allowed 
O NH2
HNS
O
N
Figure 1 The structure of the newly synthesized anticancer agent (compound 1).
Note: compound 1, 3-amino-5-oxo-N-naphthyl-5,6,7,8-tetrahydrothieno[2,3-b]
quinoline-2-carboxamide.
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to attach overnight. Cells were then treated with complete 
media or individual solutions of compound 1 at 0.5, 1, 5, 
10 and 25 μM in complete media, in triplicate, for 4, 24, 
48 and 72 h. The same compound 1 concentrations were 
tested in combination with paclitaxel. The concentration 
of paclitaxel was 40 nM for MDA-MB-231 and 12 nM for 
Du-145 cells.24,25 Following treatment, cells were incubated 
with 0.5 mg/mL MTT in media for 1 h, and then the media 
were removed and DMSO was added. Absorbance was mea-
sured at 570 nm (signal) and 690 nm (background).
Flow cytometric analysis
An equal numbers of cells (5×105) were seeded in six-well 
plates and treated with 2 μM compound 1 and/or paclitaxel 
for 48 h and then analyzed for apoptosis. A combination 
of Annexin-V-FITC and propidium iodide staining allows 
the distinction between early (Annexin-V+/PI−) and late 
(Annexin-V+/PI+) apoptotic cells, necrotic cells and live 
cells. After treatment with compound 1, paclitaxel or 
their combination, the cells were trypsinized, washed 
with phosphate-buffered saline (PBS) and resuspended in 
100 μL of the binding buffer containing 5 μL Annexin-V-
FITC and/or 5 μL of propidium iodide (Annexin-V-FITC 
Apoptosis Detection Kit I; BD Biosciences). The cells 
were incubated for 15 min at room temperature in the dark 
and thereafter analyzed by flow cytometry (BD Accuri 
C6; BD Biosciences). The percentages of apoptotic cells 
(Annexin-V-positive cells) were analyzed using the Flow-
Logic Software (Inivai) and presented as mean ± standard 
deviation (SD).
In addition, cells treated with compound 1 and/or pacli-
taxel for 48 h, as well as the controls, were trypsinized and 
washed with PBS. Cells were pretreated with an Fc receptor-
blocking reagent (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany) to prevent nonspecific binding. After 15 min of 
incubation with diluted anti-CD15s (BD Biosciences) at room 
temperature, cells were incubated with diluted anti-CD44-
FITC (BD Biosciences), anti-CD24-PE (eBioscience, Inc., 
San Diego, CA, USA) and secondary antibody conjugated 
with eFluor 660 fluorochrome (eBioscience, Inc.) for 15 min 
in the dark, resuspended in PBS and thereafter analyzed 
by flow cytometry (BD Accuri C6; BD Biosciences). The 
procedure for determination of GM3 was the same with the 
exception of incubation with anti-GM3 (NeuAc; Cosmo Bio 
Co, Tokyo, Japan) instead of anti-CD15s. Antibodies were 
diluted (Table S1).
Data acquisition of triple-stained samples was 
performed on a BD Accuri 6 cytometer and analyzed using 
the FlowLogic Software. CD44+ cells were gated, and 
CSCs were determined. GM3 and CD15s were determined 
on CSCs.
statistical analysis
For statistical analyses, one-way ANOVA followed by 
post-hoc Tukey test was performed using statistical software 
Statistica for Windows version 7.0 (Stat Soft, Tulsa, OK, 
USA) with the significance set at P,0.05.
Results
compound 1 produces a dose- and time-
dependent cytotoxicity
In this study, we compared cell viability after 4, 24, 48 and 
72 h of treatment with compound 1 using the MTT assay 
(Figure 2).
IC
50
 value for MDA-MB-231 cells was 10.9, 9.5, and 6.7 μM 
after 24, 48 and 72 h of treatment, respectively. IC
50
 value for 
Du-145 cells was 5.1 μM after 72-h treatment.
Dose- and time-dependent growth retardation was regular 
for MDA-MB-231 cells. After 4-h treatment with only 25 μM 
compound 1 showed significant effect on decrease in cell 
viability as compared to non-treated cells (100% of viability, 
cell survival =1, Figure 2). At 24 h, there was a significant 
decrease in cell viability with 5 μM of compound 1, and after 
48 h with as little as 1 μM of compound 1 (Figure 2A).
After 4 h, treatment with 10 and 25 μM compound 1 showed 
a significant decrease in Du-145 cell viability compared 
with non-treated cells (100% of viability, cell survival =1, 
Figure 2C). Du-145 cells showed similar growth after 24 h 
as MDA-MB-231 cells with the exception of treatment with 
25 μM compound 1. This may be due to poor water solubility 
of compound 1. At higher concentrations, it might be forming 
a suspension, which lowers the active concentration of the 
compound in the solution.
After 48 and 72 h, lower concentrations of compound 1 
were more cytotoxic to Du-145 in comparison to MDA-MB-
231 cells (Figure 2C).
MTT assay was also performed after paclitaxel treatment 
and after combined treatment with paclitaxel and a dilution 
curve (0.5–25 μM) of compound 1. The combination of pacli-
taxel with 0.5, 1 and 5 μM compound 1 showed a decrease 
in cell survival of MDA-MB-231 cells after 4 h. After 24 h, 
a significant decrease was noticed after treatment with 1 μM 
compound 1 and paclitaxel for MDA-MB-231 cells and at 
10 and 25 μM compound 1 and paclitaxel for Du-145 cells. 
In MDA-MB-231 cell line, paclitaxel in combination with 
higher compound 1 concentrations showed antagonistic 
effect, that is, increased cell survival. Possible antagonistic 
effects could be caused by changed glycosphingolipid 
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
16
0.
5.
16
4.
11
3 
on
 2
8-
Fe
b-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2017:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
762
Mastelić et al
GM3 expression after PLC inhibitor treatment as it will be 
discussed. Results showing decreased cell survival were 
significant for 0.5–25 μM compound 1 and paclitaxel treat-
ment after 48 and 72 h for both cell lines. In this combined 
treatment, regular concentration/cytotoxicity relationship was 
lost for both cell lines. Lower concentrations (0.5–1 μM) of 
compound 1 were more effective if combined with paclitaxel 
(Figure 2B and D). With this result, we decided to test the 
type of cell death and to determine CSC glycophenotype 
using 2 μM compound 1.
compound 1-induced cell death of breast 
cscs occurs mainly by apoptosis
To determine whether the MTT findings are due to cell death 
or cell cycle arrest, we subsequently determined the type of 
cell death induced by 48-h treatment with 2 μM compound 1 
and/or paclitaxel (40 nM for breast and 12 nM for prostate 
cancer cells).24,25 The majority of cells from both cell lines died 
by treatment-induced apoptosis (Figure 3). Compound 1 alone 
showed significant increase in early apoptosis in MDA-MB-
231 cells compared with non-treated cells. The percentage of 
Figure 2 cell viability after drug treatment.
Notes: compound 1 produces a dose- and time-dependent metabolic defect in MDa-MB-231 cell line (A). cells were treated with a dose-dependent curve of 1 as shown 
in the figure for 4, 24, 48 and 72 h and cell metabolism evaluated by the MTT assay (A, C). Metabolic defect is augmented in combination of compound 1 with 40 and 12 
nM paclitaxel for MDa-MB-231 (B) and Du-145 (D) cell line, respectively. Data represent the mean ± sD. columns, mean of viable cells; bars, sD; *P,0.05; **P,0.01; 
***P,0.001.
Abbreviation: sD, standard deviation.
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Du-145 early apoptotic cells was not changed after treatment 
with compound 1, and it was only slightly enhanced after 
paclitaxel treatment. The combination of both drugs, however, 
significantly enhanced the percentage of early apoptotic cells 
compared with non-treated Du-145 cells. The percentage of 
Du-145 apoptotic cells was decreased after treatment with 
compound 1. The percentage of Du-145 necrotic cells was 
increased after treatment with compound 1, as well as after 
treatment with paclitaxel. The percentage of MDA-MB-231 
early apoptotic cells was three times higher after combined 
treatment compared with non-treated MDA-MB-231 cells. 
Possible antagonistic effects of compound 1 and paclitaxel in 
modulating apoptosis could be caused by changed glycosphin-
golipid GM3 expression after PLC inhibitor treatment as will 
be discussed. The percentage of MDA-MB-231 necrotic cells 
was not so affected by different treatments.
compound 1 leads to a decrease in 
number of breast cscs
In breast and prostate cancer cell lines, such as MDA-MB-231 
and Du-145, a subset of markers, including CD44+/CD24−, 
has been shown to enrich CSCs.1,2 To investigate whether 
compound 1 could influence the phenotypic profile of 
cancer cell subpopulations, expression of CD44 and CD24 
surface markers was evaluated in cells treated with 2 μM 
compound 1 and/or paclitaxel (40 nM for breast and 12 nM 
for prostate cancer cells). Treatment with compound 1 
alone shows slight, but statistically significant decrease 
in the CD44+/CD24− subpopulation from 99.09%±0.53% 
(untreated control) to 96.78%±1.03% in MDA-MB-231 cell 
culture. Paclitaxel caused non-significant increase in CSCs 
percentage in both cell lines as compared with the control. 
Our finding of increased CSCs percentage after paclitaxel 
alone treatment corresponds to finding by others.26 Com-
bined treatment with paclitaxel and compound 1 abolished 
the effect of compound 1 in reducing CSCs with paclitaxel 
increasing CSCs more efficiently than the decrease induced 
by compound 1. The same subpopulation was significantly 
increased in Du-145 cell culture (Figure 4). A combination 
of both drugs only significantly changed the Du-145 cells to 
higher percentage of CSCs.
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Figure 3 apoptosis after drug treatment.
Notes: apoptosis after treatment with 2 μM compound 1 combined with 40 or 12 nM paclitaxel, in duration of 48 h in MDa-MB-231 or Du-145 cell lines, respectively. Data 
represent the mean ± sD of annexinV+/Pi− cells. columns, mean of cells; bars, sD; *P,0.05 and **P,0.01.
Abbreviation: sD, standard deviation.
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compound 1 increases gM3 expression 
of breast cscs and lowers percentage of 
prostate gM3+ csc subpopulation
GM3 ganglioside expression was studied in CSCs with the 
aim to check whether the cytotoxic effects of compound 1 
are mediated via GM3 membrane content. GM3 GMI (GM3 
expression/cell) was increased in CSC MDA-MB-231 cells 
after treatment with compound 1, whereas GM3 GMI of CSC 
Du-145 was unaffected (Figure 5A and B). However, com-
pound 1 did not influence the percentage of GM3+ MDA-MB-
231 CSCs but, alone, as well as in combination with paclitaxel, 
it lowered the percentage of Du-145 GM3+ CSCs (Figure 6).
Compound 1 does not influence CD15s 
expression but it lowers the percentage 
of cD15s+ cscs in both cell lines
CD15s enables malignant infiltration in different tissues; 
therefore, the impact of compound 1 on CD15s expression 
was tested. Treatment with compound 1 did not influence 
CD15s expression on CSCs of both cell lines (Figure 5C 
and D). The percentage of MDA-MB-231 and Du-145 
CD15s+ CSCs was lowered in case of treatment with com-
pound 1 while combined treatment decreased the percentage 
of Du-145 CD15s+ CSCs (Figure S1).
Discussion
Aberrant glycosylation can increase cancer cell metastatic 
ability.27 The focus of our interest was GM3 and CD15s 
glycoconjugate expression on the surface of CSCs that are 
responsible for tumor relapse and resistance to therapy. 
We found that newly synthesized putative PLC inhibitor, 
3-amino-5-oxo-N-naphthyl-5,6,7,8-tetrahydrothieno[2,3-b]
quinoline-2-carboxamide (compound 1; Figure 1) was 
cytotoxic for both breast MDA-MB-231 and prostate Du-145 
cancer cells. Tenfold difference in IC
50
 value for MDA-MB-
231 cell line is due to the fact that thymidine uptake assay 
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Figure 4 csc (cD44+/cD24−) after drug treatment.
Notes: Percentage of cscs after treatment with 2 μM compound 1 combined with 40 or 12 nM paclitaxel, in duration of 48 h in MDa-MB-231 or Du-145 cell lines, 
respectively. Data represent the mean ± sD. columns, mean of cells; bars, sD; *P,0.05.
Abbreviations: cscs, cancer stem cells; sD, standard deviation.
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measures thymidine incorporation into the DNA where cell 
division is active. MTT assay used in our experiment mea-
sures viable cells regardless whether the cells are undergo-
ing active cell division or not. As the compound may be a 
cytostatic drug that induced cells to a G2/M phase cell cycle 
arrest, the discrepancy in the IC
50
 measured is likely to be 
contributed by the different methods of analysis.
Determination of the type of cell death showed that 
compound 1-induced cell death of breast CSCs occurred 
mainly by apoptosis. In addition, breast cell population showed 
a lower percentage of CSC subpopulation, unchanged per-
centage of GM3+ CSC subpopulation, while GM3 expression/
CSC was significantly increased. However, the extent of 
prostate CSC apoptosis and GM3 expression/CSC was not 
significantly changed after treatment with compound 1. CSC 
subpopulation percentage in total prostate cell population 
was significantly increased while the percentage of the GM3+ 
prostate CSC subpopulation was significantly decreased. 
Therefore, it can be assumed that the increase in apoptosis 
and lowered percentage of CSC subpopulation are mediated 
by increased GM3 expression on MDA-MB-231 CSCs. This 
assumption is in accordance with a recent finding that GM3 
mediates cisplatin-induced apoptosis in human colon cancer 
cells.28 GM3 is known to inhibit tyrosine kinases associ-
ated with epidermal and fibroblast growth factor receptors 
(EGF and FGF receptors).29,30 EGF receptor is functional in 
prostate Du-145 cells,31 while breast MDA-MB-231 cells 
express EGF receptor but lack a proliferative response to 
EGF.32 Both cell lines possess FGF receptors. When human 
embryonic fibroblasts adhere, they give rise to signaling 
to activate FGF receptor through tyrosine phosphorylation 
and inducing cell proliferation under serum-free conditions 
without FGF addition.33 FGF can increase PLC-δ activity 
and enhance cell proliferation.34 Cell lines in this study were 
grown in 10% fetal bovine serum and ordinary FGF signal-
ing was expected to happen. Among the PLC isozymes, 
primary PLCs, PLC-β and PLC-γ are directly activated by 
receptor activation, unlike other secondary PLCs (PLC-ε, 
PLC-δ1 and PLC-η1).35 The PLC-δ is the most important 
among all PLCs. Loss of function in PLC-δ gene-deficient 
mice has revealed the critical function of PLC isozymes as 
a key molecule of cellular functions.36 Receptor-mediated 
PLC (β and/or γ) activation is usually transient and rapidly 
desensitized, while the positive Ca2+-inositol phospholipid 
loop, that activates PLC-δ1, could prolong the action of 
receptor-activated PLC and may operate in slower or more 
prolonged cellular responses.37 PLC-β isozymes are activated 
by G-protein-coupled receptor and PLC-γ isozymes are acti-
vated by receptor tyrosine kinase as it is an FGF receptor.35 
We can assume that FGF produces short transient activation 
of PLC-γ in our MDA-MB-231 cell line experiment. Due to 
action of inhibitor 1 treatment, calcium released after PLC-γ 
Figure 5 GM3 and CD15s geometric mean fluorescence of CSC after drug treatment.
Notes: GM3 and CD15s geometric mean fluorescence of CSC after treatment with 2 μM compound 1 combined with 40 or 12 nM paclitaxel, in duration of 48 h in MDa-
MB-231 (A, C) or Du-145 (B, D) cell lines, respectively. Data represent the mean ± sD. columns, mean of viable cells; bars, sD; ***P,0.001.
Abbreviations: CSCs, cancer stem cells; GMI, geometric mean fluorescence intensity; SD, standard deviation.
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action cannot induce prolonged PLC-δ1 activity, resulting in 
lower cell proliferation.
The lack of the same response of Du-145 cells to the PLC 
inhibitor (unchanged apoptosis and increased CSC percent-
age) might be regulated through PLC, protein kinase C (PKC) 
and EGF receptor interactions. Wells et al hypothesized 
that luteinizing hormone-releasing hormone triggers PLC 
to activate PKC, and PKC activation limits EGF receptor 
tyrosine kinase activity by phosphorylating EGF receptor 
at threonine 654 in Du-145 cells.31 Further experiments will 
resolve whether the difference in response to compound 1 
between Du-145 cells and MDA-MB-231 is due to their 
known difference in EGF receptor response.31,32
Enhanced GM3 expression per each CSC in the MDA-
MB-231 cell line experiment could inhibit cell proliferation 
by blocking FGF receptor phosphorylation. Anti-GM3 
antibody used in this study was developed against GM3 Anti-
GM3 antibody used in this study was developed against GM3 
substituted with N-acetyl neuraminic acid -GM3(NeuAc). 
Resorcinol thin-layer chromatography staining of total 
MDA-MB-231 cell ganglioside extract detected GM3 
(NeuAc) as the major ganglioside fraction.6 Authors have 
not used GM3 (NeuGc) standard, but the fraction clearly 
visible on published chromatogram below GM3 (NeuAc) 
can be GM3 (NeuGc) or GM3 (NeuAc) with shorter fatty 
acid or sphingosine hydrophobic chain.6 GM3 (NeuGc) is 
chromatographed below GM3 (NeuAc) due to higher affinity 
to hydrophilic silica-gel stationary phase and lower affinity 
to hydrophobic mobile phase.38 It is important to distinguish 
GM3 (NeuAc) and GM3 (NeuGc) ganglioside fractions, the 
latter leading to more malignant phenotype.8 Overexpression 
or neo-expression of gangliosides in breast cancer has been 
usually demonstrated. GM3 (NeuGc) has been detected in 
invasive ductal carcinomas, with 100% efficiency in primary 
tumors for women diagnosed with stage II breast cancer.39 
Neu5Gc is not present in humans because the gene encoding 
the CMP-Neu5Ac hydroxylase is irreversibly inactivated. 
The absence of the enzyme responsible for the conversion 
of CMP-Neu5Ac to CMP-Neu5Gc leads to the total absence 
of Neu5Gc in healthy human tissues. However, Neu5Gc was 
shown to be expressed on glycoproteins and gangliosides in 
breast cancers.39
Figure 6 Percentage of gM3+ cscs after drug treatment.
Notes: Percentage of gM3+ csc after treatment with 2 μM compound 1 combined with 40 or 12 nM paclitaxel, in duration of 48 h in MDa-MB-231 or Du-145 cell lines, 
respectively. Data represent the mean ± sD. columns, mean of cells; bars, sD; *P,0.05 and **P,0.01.
Abbreviations: cscs, cancer stem cells; sD, standard deviation.
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Using resorcinol staining of thin-layer chromatogram, 
GM3 was detected in total Du-145 cell ganglioside extract 
as the minor fraction.7 Treatment with compound 1 resulted 
in an unchanged GM3 expression/Du-145 CSC in compari-
son to control cells. GM3 is the minor ganglioside fraction 
of Du-145 cells7 and probable induction of GM3 synthesis, 
due to PLC inhibition, could result in increased conversion 
to GD1a, the major Du-145 ganglioside fraction. On the 
contrary, the same mechanism in MDA-MB-231 cells would 
result in higher expression of the GM3, its major ganglioside 
fraction6 as was found in this study.
In addition to GM3, we analyzed CD15s glycoconjugate, 
the major ligand of endothelial (E) selectin, responsible 
for cancer cell metastasizing. In the case of CD15s gly-
cosphingolipid, [NeuAc-Gal-(Fuc)-GlcNAc] glycoantigen 
is linked to a ceramide anchor in the outer leaflet of the 
plasma membrane. In the case of CD15s glycoprotein, the 
same glycoantigen is linked to CD11b or CD44 transmem-
brane glycoprotein.40 CD44 variant isoform 4 (CD44v4) is 
a major metastatic MDA-MB-231 glycoprotein decorated 
with CD15s moieties and serves as an E-selectin ligand in 
facilitating tumor cell metastasis.41 It was shown that tumor 
spheroid/aggregate grown MDA-MB-231 unregulated their 
CD15s expression and demonstrate the most robust rolling 
behavior on E-selectin-coated surfaces, compared with 
MDA-MB-231 cells from plasma and cytokine treatments.42 
In this study, CD15s expression per one CSC was not 
changed while the percentage of CD15s+ CSCs was lower 
in both cell lines after treatment with compound 1. That 
means, a lower percentage of CSCs possesses metastatic 
potential after PLC inhibition. Similarly, the beneficial effect 
of paclitaxel treatment was lowering of CD15s+ CSCs in 
both cell lines but this effect was weaker in comparison to 
treatment with compound 1.
The beneficial effect of treatment with both drugs 
(1+paclitaxel) is increased GM3 expression/CSC in MDA-
MB-231 cells. This increase was weaker in comparison with 
the effect of treatment with compound 1 alone. In MDA-
MB-231 cell line, paclitaxel in combination with higher 
concentrations of compound 1 showed antagonistic effect, 
that is, increased cell survival. There are no data in literature 
on paclitaxel influence upon GM3 expression, but there is 
the evidence about GM3 attenuation of paclitaxel-triggered 
apoptosis in ovarian cancer cells.43 Our finding of decreased 
apoptosis after combined drug treatment in MDA-MB-231 
cell line is in accordance with this reference.43
Furthermore, determinations of apoptosis and CSCs after 
treatment with a combination of compound 1 and paclitaxel 
gave ambiguous results for androgen-independent prostate 
cancer cells. The apoptosis of Du-145 cells was increased 
after treatment with both drugs, but the percentage of CSCs 
was higher after combined drug treatment. More types of 
experiments should be performed to clarify the effect of 
combined compound 1 and paclitaxel treatment.
We demonstrated that treatment of human MDA-MB-
231 triple-negative breast cancer cells with derivative 1 
resulted in higher apoptosis and GM3 expression/CSC, and 
lower percentages of CSC subpopulation and CD15s+ CSCs. 
Considering that triple-negative breast cancers are character-
ized by an increased percentage of breast CSCs and knowing 
their association with an increased risk of metastasis and 
mortality, compound 1 deserves attention as a potential new 
drug for triple-negative breast cancer therapy.
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Supplementary materials
Table S1 Diluted antibodies
Antibody Original antibody:PBS
anti-cD15s 1:3
eFluor 660 fluorochrome 1:10
anti-cD24-Pe 1:3
anti-cD44-FiTc 1:13
anti-gM3 1:4
Note: antibodies were diluted in PBs.
Abbreviation: PBs, phosphate-buffered saline.
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Figure S1 Percentage of cD15s+ cscs after drug treatment.
Notes: Percentage of cD15s+ cscs after treatment with 2 μM compound 1 combined with 40 or 12 nM paclitaxel, in duration of 48 h in MDa-MB-231 or Du-145 cell lines, 
respectively. Data represent the mean ± sD. columns, mean of cells; bars, sD; *P,0.05, **P,0.01 and ***P,0.001.
Abbreviations: cscs, cancer stem cells; sD, standard deviation.
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